Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Withdrawal in Patients With Coronary Artery Disease.

Journal of the American College of Cardiology·2026
Same author

Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.

JAMA network open·2026
Same author

Additive value of polygenic risk and family history for coronary heart disease risk stratification in two diverse US cohorts.

American journal of human genetics·2026
Same author

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Clinical and translational science·2026
Same author

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.

Surgery·2026
Same author

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.

Surgical endoscopy·2026

Related Experiment Video

Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Warfarin pharmacogenomics.

Larisa H Cavallari1, Nita A Limdi

  • 1University of Illinois at Chicago, Department of Pharmacy Practice, Chicago, IL 60612, USA. humma@uic.edu

Current Opinion in Molecular Therapeutics
|May 30, 2009
PubMed
Summary

Warfarin dosing is complex due to genetic factors like CYP2C9 and VKORC1. While genotype improves dose prediction, current evidence does not support routine genetic testing for better patient outcomes.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Genetics

Background:

  • Warfarin therapy presents challenges due to its narrow therapeutic index and significant interpatient dose variability.
  • Genetic variations in cytochrome P450 (CYP)2C9 and vitamin K epoxide reductase complex 1 (VKORC1) influence warfarin dose requirements.

Purpose of the Study:

  • To investigate the association between CYP2C9 and VKORC1 genetic variants and warfarin dose requirements.
  • To explore racial differences in genotype-response relationships for warfarin therapy.
  • To assess the impact of genotype information on anticoagulation control and bleeding risk.

Main Methods:

  • Analysis of CYP2C9*2, CYP2C9*3, and VKORC1 -1639A allele frequencies.
  • Correlation of genetic variants with warfarin dose, time to therapeutic anticoagulation, and hemorrhagic complications.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

  • Comparison of genotype-clinical factor associations across different racial groups.

    • Main Results:

    • Reduced warfarin doses are needed for patients with variant CYP2C9 or VKORC1 alleles.
    • Genotype and clinical factors explain 50-60% of dose variance in Caucasians/Asians, but only 25-40% in African Americans.
    • Genotype influences time to anticoagulation and bleeding risk, but does not demonstrably improve control or reduce complications.

    Conclusions:

    • Incorporating CYP2C9 and VKORC1 genotype information enhances warfarin dose prediction accuracy.
    • Current evidence does not support the routine clinical use of CYP2C9 and VKORC1 genotyping for managing warfarin therapy.
    • Further multicenter trials are needed to clarify the role of pharmacogenomics in optimizing warfarin treatment.